Svoboda | Graniru | BBC Russia | Golosameriki | Facebook
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Immunosenescence and Vaccine Immune Responses
share announcement

Immunosenescence and Vaccine Immune Responses

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 1078

Special Issue Editor

Dr. Qihan Li

E-Mail Website
Guest Editor
Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming 650118, China
Interests: vaccination; immune responses; immunosenescence

Special Issue Information

Dear Colleagues,

This Special Issue is focused on the impaired immunity with age or other related special pathological processes, a phenomenon called immunosenescence, resulting in an increased vulnerability of individuals to infectious diseases, age-related inflammatory diseases and also a diminished response to vaccination. The collection within this Special Issue aims to gather original articles and reviews or communications that offer insight into the underlying biology of immunosenescence, immune response to vaccines, the assessment of cellular and humoral immune responses induced by vaccines, the durability of antibody and cellular immunity, response differences associated with varying vaccine platforms, differences in vaccine populations, innate responses in vaccine-mediated protection, etc.

Dr. Qihan Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immune response
  • vaccine
  • immunosenescence
  • age

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 322 KiB  
Review
Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age
by Georgios Papazisis, Xanthippi Topalidou, Georgia Gioula, Pablo A. González, Susan M. Bueno and Alexis M. Kalergis
Vaccines 2024, 12(4), 353; https://doi.org/10.3390/vaccines12040353 - 25 Mar 2024
Viewed by 887
Abstract
Immunosenescence refers to age-related alterations in immune system function affecting both the humoral and cellular arm of immunity. Understanding immunosenescence and its impact on the vaccination of older adults is essential since primary vaccine responses in older individuals can fail to generate complete [...] Read more.
Immunosenescence refers to age-related alterations in immune system function affecting both the humoral and cellular arm of immunity. Understanding immunosenescence and its impact on the vaccination of older adults is essential since primary vaccine responses in older individuals can fail to generate complete protection, especially vaccines targeting infections with increased incidence among the elderly, such as the respiratory syncytial virus. Here, we review clinical trials of both candidate and approved vaccines against respiratory syncytial virus (RSV) that include adults aged ≥50 years, with an emphasis on the evaluation of immunogenicity parameters. Currently, there are 10 vaccine candidates and 2 vaccines approved for the prevention of RSV in the older adult population. The number of registered clinical trials for this age group amounts to 42. Our preliminary evaluation of published results and interim analyses of RSV vaccine clinical trials indicates efficacy in older adult participants, demonstrating immunity levels that closely resemble those of younger adult participants. Full article
(This article belongs to the Special Issue Immunosenescence and Vaccine Immune Responses)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop